Advertisement
REPL vs XENE
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REPL is a StrongBuy and XENE is a Buy.
REPL in upward trend: price may jump up because it broke its lower Bollinger Band on October 16, 2026
REPL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 47 of 54 cases where REPL's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where REPL's RSI Oscillator exited the oversold zone, 36 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 59 cases where REPL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
Following a +4.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where REPL advanced for three days, in 184 of 244 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on REPL as a result. In 72 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for REPL turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 42 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
REPL moved below its 50-day moving average on October 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for REPL crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REPL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for REPL entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. REPL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.221) is normal, around the industry mean (3.035). P/E Ratio (-3.638) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REPL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
XENE's RSI Oscillator ascends from oversold territory
The RSI Oscillator for XENE moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 21 of the 27 cases the stock moved higher. This puts the odds of a move higher at 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for XENE just turned positive on October 07, 2026. Looking at past instances where XENE's MACD turned positive, the stock continued to rise in 37 of 49 cases over the following month. The odds of a continued upward trend are 76%.
Following a +8.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where XENE advanced for three days, in 195 of 290 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
XENE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XENE as a result. In 72 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
The 50-day moving average for XENE moved below the 200-day moving average on October 13, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XENE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
The Aroon Indicator for XENE entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 66 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.755) is normal, around the industry mean (3.035). P/E Ratio (-7.456) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (1.930) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (588.235) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. XENE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
REPL | XENE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 77 Overvalued | 76 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 66 | |
SMR RATING 1..100 | 99 | 97 | |
PRICE GROWTH RATING 1..100 | 34 | 79 | |
P/E GROWTH RATING 1..100 | 53 | 10 | |
SEASONALITY SCORE 1..100 | 90 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XENE's Valuation (76) in the Biotechnology industry is in the same range as REPL (77). This means that XENE’s stock grew similarly to REPL’s over the last 12 months.
XENE's Profit vs Risk Rating (66) in the Biotechnology industry is somewhat better than the same rating for REPL (100). This means that XENE’s stock grew somewhat faster than REPL’s over the last 12 months.
XENE's SMR Rating (97) in the Biotechnology industry is in the same range as REPL (99). This means that XENE’s stock grew similarly to REPL’s over the last 12 months.
REPL's Price Growth Rating (34) in the Biotechnology industry is somewhat better than the same rating for XENE (79). This means that REPL’s stock grew somewhat faster than XENE’s over the last 12 months.
XENE's P/E Growth Rating (10) in the Biotechnology industry is somewhat better than the same rating for REPL (53). This means that XENE’s stock grew somewhat faster than REPL’s over the last 12 months.
| REPL | XENE | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 86% | 3 days ago 78% |
| Stochastic ODDS (%) | 3 days ago 81% | 3 days ago 81% |
| Momentum ODDS (%) | 3 days ago 88% | 3 days ago 77% |
| MACD ODDS (%) | 3 days ago 84% | 3 days ago 76% |
| TrendWeek ODDS (%) | 3 days ago 82% | 3 days ago 72% |
| TrendMonth ODDS (%) | 3 days ago 83% | 3 days ago 71% |
| Advances ODDS (%) | 4 days ago 75% | 6 days ago 67% |
| Declines ODDS (%) | 12 days ago 84% | 12 days ago 68% |
| BollingerBands ODDS (%) | 3 days ago 87% | 3 days ago 74% |
| Aroon ODDS (%) | 3 days ago 79% | 3 days ago 73% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
REPL’s FA Score shows that 0 FA rating(s) are green while XENE’s FA Score has 1 green FA rating(s).
- REPL’s FA Score: 0 green, 5 red.
- XENE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
REPL’s TA Score shows that 4 TA indicator(s) are bullish while XENE’s TA Score has 4 bullish TA indicator(s).
- REPL’s TA Score: 4 bullish, 6 bearish.
- XENE’s TA Score: 4 bullish, 5 bearish.
Price Growth
REPL (@Biotechnology) experienced а +5.52% price change this week, while XENE (@Biotechnology) price change was +5.52% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was -16.30%, and the average quarterly price growth was -16.78%.
Reported Earning Dates
REPL is expected to report earnings on Oct 28, 2026.
XENE is expected to report earnings on Nov 02, 2026.
Industries' Descriptions
@Biotechnology (+1.24% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DPRE | 24.86 | N/A | N/A |
| Virtus Duff & Phelps Real Estate Income ETF | |||
| UBND | 20.92 | -0.02 | -0.10% |
| VictoryShares Core Plus Bond ETF (UBND) | |||
| ESSC | 28.45 | -0.05 | -0.16% |
| Eventide Small Cap ETF (ESSC) | |||
| SIXD | 31.29 | -0.16 | -0.51% |
| AllianzIM U.S. Equity 6 Month Buffer10 Jun/Dec ETF (SIXD) | |||
| KSLV | 20.42 | -0.33 | -1.59% |
| Kurv Silver Enhanced Income ETF (KSLV) | |||
XENE and
Correlation & Price change
A.I.dvisor indicates that over the last year, XENE has been loosely correlated with RLMD. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then RLMD could also see price increases.
| Ticker / NAME | Correlation To XENE | 1D Price Change % | ||
|---|---|---|---|---|
| XENE | 100% | -3.18% | ||
| RLMD - XENE | 50% Loosely correlated | -0.61% | ||
| DNTH - XENE | 45% Loosely correlated | -2.23% | ||
| MLTX - XENE | 44% Loosely correlated | -3.97% | ||
| REPL - XENE | 42% Loosely correlated | -4.42% | ||
| DYN - XENE | 39% Loosely correlated | -0.95% | ||
More | ||||